ReviewHematology. American Society of Hematology. Education Program2011
Aggressive B-cell lymphomas: a review of new and old entities in the WHO classification.
Review in Hematology. American Society of Hematology. Education Program, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 109 citations in OpenAlex.
- Clinical significance of MYC expression and/or "high-grade" morphology in non-Burkitt, diffuse aggressive B-cell lymphomas: a SWOG S9704 correlative study.The American journal of surgical pathology · 2014Trial
- Aggressive Mandibular Plasmablastic Lymphoma in an HIV-Negative Patient: Clinicopathologic and Immunophenotypic Insights From a Rare Oral Case.Case reports in dentistry · 2026Article
- Alectinib shows promise for the treatment of refractory ALK-positive large B-cell lymphoma: a case report.Frontiers in oncology · 2026Article
- Evaluation of Bruton's Tyrosine Kinase (BTK) inhibition with alternative doses of ibrutinib in subjects with Chronic Lymphocytic Leukemia (CLL).Cancer chemotherapy and pharmacology · 2025Article
- Using a Natural Triterpenoid to Unlock the Antitumor Effects of Autophagy in B-Cell Lymphoma.Biomedicines · 2025Article
- Prevalence of Epstein-Barr Virus in Patients with Intraocular Inflammation.Ocular immunology and inflammation · 2023Observational
- Copanlisib plus rituximab combination therapyAnnals of translational medicine · 2022Article
- Novel Biological Insights and New Developments in Management of Burkitt Lymphoma and High-Grade B-Cell Lymphoma.Current treatment options in oncology · 2021Review
- SPAG6 promotes cell proliferation and inhibits apoptosis through the PTEN/PI3K/AKT pathway in Burkitt lymphoma.Oncology reports · 2020Article
- Intraoral plasmablastic lymphoma as a primary oral manifestation: A case report and review of literature.Journal of oral and maxillofacial pathology : JOMFP · 2020Article
- Isolation and characterization of a CD34Oncotarget · 2020Article
- Non-Hodgkin's Lymphoma: An Important Differential Diagnosis in Inflammatory Bowel Disease.Chinese medical journal · 2018Article
- EBV-positive Reactive Hyperplasia Progressed into EBV-positive Diffuse Large B-cell Lymphoma of the Elderly over a 6-year Period.Internal medicine (Tokyo, Japan) · 2018Article
- Mitochondrial and glycolytic metabolic compartmentalization in diffuse large B-cell lymphoma.Seminars in oncology · 2017Article
- Burkitt lymphoma expresses oncofetal chondroitin sulfate without being a reservoir for placental malaria sequestration.International journal of cancer · 2017Article
- Plasmablastic Lymphoma with Coexistence of Chronic Lymphocytic Leukemia in an Immunocompetent Patient: A Case Report and Mini-Review.Case reports in hematology · 2017Article
- Article
- GNA13 loss in germinal center B cells leads to impaired apoptosis and promotes lymphoma in vivo.Blood · 2016Article
- Article
- MYC-driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical management.Oncotarget · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Aggressive B-cell lymphomas are clinically and pathologically diverse and reflect multiple pathways of transformation. The 2008 World Health Organization (WHO) classification reflects this complexity with the addition of several new entities and variants. Whereas MYC translocations have long been associated with Burkitt lymphoma (BL), deregulation of MYC has been shown to occur in other aggressive B-cell lymphomas, most often as a secondary event. Lymphomas with translocations of both MYC and BCL2 are highly aggressive tumors, with a high failure rate with most treatment protocols. These "double-hit" lymphomas are now separately delineated in the WHO classification as B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma (DLBCL) and BL. A MYC translocation is also found uncommonly in DLBCL, but the clinical consequences of this in the absence of a double hit are not yet fully delineated. Most recently, MYC translocations have been identified as a common secondary event in plasma cell neoplasms, seen in approximately 50% of plasmablastic lymphoma. Another area that has received recent attention is the spectrum of EBV-driven B-cell proliferations in patients without iatrogenic or congenital immunosuppression; most of these occur in patients of advanced age and include the EBV-positive large B-cell lymphomas of the elderly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.